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based on the all-procedure trimmed mean. The manufactur-
ers recalibrated their assays against these targets.  Results: 
All FT4 assays were negatively biased in the mid- to high con-
centration range, with a maximum interassay discrepancy of 
approximately 30%. However, in the low range, the maxi-
mum deviation was approximately 90%. For TSH, interassay 
comparability was reasonable in the mid-concentration 
range, but worse in the pathophysiological ranges. Recali-
bration was able to eliminate the interassay differences, so 
that the remaining dispersion of the data was nearly entirely 
due to within-assay random error components. The impact 
of recalibration on the numerical results was particularly 
high for FT4.  Conclusions: Standardization and harmoniza-
tion of FT4 and TSH measurements is feasible from a techni-
cal point of view. Because of the impact on the numerical 
values, the implementation needs careful preparation with 
the stakeholders.  © 2014 European Thyroid Association
Published by S. Karger AG, Basel 
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 Abstract 
 Background: The IFCC Committee for Standardization of 
Thyroid Function Tests aims at equivalence of laboratory test 
results for free thyroxine (FT4) and thyrotropin (TSH). Objec-
tives: This report describes the phase III method comparison 
study with clinical samples representing a broad spectrum 
of thyroid disease. The objective was to expand the feasibil-
ity work and explore the impact of standardization/harmo-
nization in the clinically relevant concentration range.  Meth-
ods: Two sets of serum samples (74 for FT4, 94 for TSH) were 
obtained in a clinical setting. Eight manufacturers participat-
ed in the study (with 13 FT4 and 14 TSH assays). Targets for 
FT4 were set by the international conventional reference 
measurement procedure of the IFCC; those for TSH were 
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 Introduction 
 It is generally accepted that laboratory medicine should 
focus on improving consistency and reproducibility of 
measurements across different laboratories and methods 
 [1, 2] . Immediate benefits to expect from accomplishing 
this goal are easy transfer and/or combined analysis of lab-
oratory data, significant reduction of repeated measure-
ments, and increased confidence in patient care. In the 
mid- to long term, development of evidence-based prac-
tice guidelines with recommendations for uniform in-
stead of assay-specific decision limits would become pos-
sible. The process to achieve this goal is called ‘standard-
ization’ and makes use of a reference measurement system 
 [3] . Typical examples of internationally standardized lab-
oratory tests include lipids, HbA1c, creatinine, and en-
zymes  [4–7] , but more are under development  [8–11] . 
 The IFCC Committee for Standardization of Thyroid 
Function Tests (C-STFT) aims at equivalence of labora-
tory testing for total and free thyroid hormones and thy-
rotropin (TSH)  [12–14] . The committee was established 
in light of the prevalence of thyroid disease, the frequency 
of laboratory testing, and multiple reports on discrepant 
measurement results. For total thyroxine/triiodothyro-
nine testing, a state-of-the-art SI-traceable reference 
measurement system was already available for imple-
mentation  [14] . For free thyroid hormones and TSH, the 
C-STFT had to start the process from scratch. The mea-
surands needed to be defined and reference measurement 
procedures or a valid alternative developed. For free thy-
roxine (FT4), this led to an IFCC-approved international 
conventional reference measurement procedure (cRMP), 
based on equilibrium dialysis isotope dilution-liquid 
chromatography-tandem mass spectrometry (ED ID-
LC/tandem MS)  [15] . In the case of TSH, for which it is 
technically unlikely to have an RMP available in the mid- 
to short term, the C-STFT proposed a statistical alterna-
tive for ‘harmonization’ rather than standardization  [16, 
17] . 
 With these two tools, the committee developed a strat-
egy to assess the quality and comparability of FT4 and 
TSH assays, followed by investigation of the feasibility of 
standardization/harmonization. This was done in coop-
eration with the in vitro diagnostic (IVD) industry and in 
essence used several method comparison studies with 
panels of single-donation sera  [12, 13, 18] . These showed 
the assays were of good quality, but confirmed consider-
able interassay difference in results. Simultaneously, they 
demonstrated the feasibility of aligning the assays. How-
ever, the conducted studies had one important limitation: 
they only used samples from apparently healthy donors 
and few samples from patients with thyroid disease. 
Therefore, C-STFT performed a phase III method com-
parison study using a wide variety of samples from pa-
tients with thyroid disease. This allowed the exploration 
of the impact of standardization/harmonization across 
the clinically relevant concentration range. This was par-
ticularly crucial for TSH in view of the evidence for thy-
roid disorder-specific glycoforms, implying that antibod-
ies in current assays may either demonstrate glycosyl-
ation-specific binding or are ‘glycosylation blind’  [19, 20] . 
 Materials and Methods 
 Panels of Clinical Samples 
 Serum samples (74 for FT4, 94 for TSH) were obtained from 
commercial sources (SLR Research Corporation, Carlsbad, Calif., 
and PromeddX, Norton, Mass., USA) working with clinical cen-
ters, and by courtesy of endocrinologists. All collection centers had 
the approval of their ethical review boards. The two serum panels 
were selected to represent the relevant clinical measurement range 
(see  table 1  for the inclusion and exclusion criteria).
 Study Participants 
 Eight IVD manufacturers participated, with a total of 13 assays 
for FT4 and 14 for TSH ( table 2 ). It is important to note that the 
assays are randomly coded, without a logical relationship between 
the FT4 and TSH assays (for the rationale, see online suppl. mate-
rial; www.karger.com/doi/10.1159/000358270).
 Target Setting of the Samples  
 FT4 target values were assigned at Ghent University with the 
ED ID-LC/tandem MS cRMP  [15] . The method’s expanded uncer-
tainty of measurement (k = 2, 95% confidence level) according to 
the measurement protocol used (3 replicates, in independent runs) 
is estimated at 7.6%. The targets for TSH were based on the all-
procedure trimmed mean (APTM) inferred by an iterative calcula-
tion process with adaptation of assay-specific outliers (see online 
suppl. material).
 Method Comparison Study and Recalibration 
 The routine assays performed duplicate measurements within 
one run with one reagent lot, and under internal quality control 
conditions selected by the respective IVD manufacturers. To as-
sure random distribution of sample concentrations, the replicates 
were measured in upward and downward sequences. The manu-
facturers included their master calibrators for use in subsequent 
recalibration.
 Data Analysis 
 Concentration range 
 For FT4, one sample with a concentration below the limit of 
quantitation of the cRMP (at 0.86 pmol/l) was excluded from data 
analysis; the same applied for 7 TSH samples with concentrations 
below the typical functional sensitivity limit (0.012 mIU/l) because 
3–6 assays did not report results.
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 Table 1.  Characteristics of the FT4 and TSH serum panel
FT4 panel TSH panel
Number of samples 74 94
Target setting ED ID-LC/tandem MS APTM
Concentration range 3 – 77 pmol/l 0.04 – 80 mIU/l
Inclusion criteria Individuals were at least 18 years old and competent to give informed consent, as considered by the physician, study nurse or 
other health care professional interviewing the patient 
Individuals being evaluated for a thyroid disorder and classified into one of the following groups (if possible evenly 
distributed):
D: hyperthyroid (n = 30)
Patients with FT4 values >28 pmol/l up to 40 pmol/la
A: hyperthyroid (n = 30)
A1: 10 patients with suppressed TSH, around 0.01 mIU/l
A2: 10 patients with TSH values between 0.01 and 0.1 mIU/l
A3: 10 patients with TSH values between 0.1 and 0.3 mIU/la
E: euthyroid (n = 120)
Patients with FT4 values between 10 and 28 pmol/la
B: euthyroid (n = 30)
Patients with TSH values between 0.3 and 3.0 mIU/la
F: hypoth yroid (n = 30)
Patients with FT4 values between 3 and 10 pmol/la
C: hypothyroid (n = 40)
C1: 20 patients with TSH values between 3.0 and 50 mIU/la
C2: 20 patients with TSH values >50 mIU/l up to 100 mIU/l
Donors treated for thyroid dysfunction were included, provided information on the type of treatment and start of the 
treatment was available 
Note: samples were measured for their endogenous analyte concentration, hence subjects treated with L-thyroxine were only 
included in the TSH panel and vice versa for patients treated with recombinant TSH
Exclusion criteria Individuals previously enrolled into this clinical study
Individuals diagnosed with a severe NTI, defined as a state of dysregulation where levels of T3, T4, FT3, and/or FT4 are 
abnormal although the thyroid gland does not appear to be dysfunctional
Individuals with known pregnancy
Patients not meeting the established inclusion criteria
 a These values are indicative because they depend on the measurement range and the reference interval of the assay used to evaluate the FT4 or TSH 
status.
 Table 2.  Study participants and assays
Assay manufacturer Assay Analyte
Abbott Diagnostics
(Abbott Park, Ill., USA)
Architect i2000SR FT4 and TSH
Beckman Coulter, Inc.
(Brea, Calif., USA)
Access 2 FT4 and TSH
bioMérieux s.a.
(Marcy-l’Etoile, France)
VIDAS FT4
VIDAS TSH & TSH3
FT4
TSH
DiaSorin S.p.A. (Saluggia, Italy) Liaison FT4 and TSH
Ortho-Clinical Diagnostics 
(Buckinghamshire, UK)
VITROS Immunodiagnostic Systems (ECiQ and 3600) FT4 and TSH
Roche Diagnostics GmbH 
(Mannheim, Germany)
Elecsys FT4 and TSH
Siemens Healthcare Diagnostics Inc. 
(Deerfield, Ill., USA)
ADVIA Centaur
ADVIA Centaur TSH3-UL
Dimension RxL 
Dimension EXL with LOCI module
Dimension EXL with LOCI module (3rd generation)
Dimension Vista 1500
IMMULITE 2000
IMMULITE 2000  (Third Generation TSH)
FT4
TSH
FT4 and TSH
FT4
TSH
FT4 and TSH
FT4
TSH
Tosoh Corporation (Tokyo, Japan) AIA-2000 (ST AIA-PACK) FT4 and TSH
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 Assay-Specific Outliers 
 Assay-specific outliers were identified from inspection of the 
scatter and difference plots (absolute, %-difference, and %-residu-
als) of the means of duplicates against the FT4 cRMP target values 
and the first APTM in the iterative process, and from the %-differ-
ence between the duplicates and the interassay CV observed for the 
samples. Outlying results were substituted with values that fit best 
in the %-residual plot, whereby both replicates were given the same 
value. This prevented that (1) the APTM for that sample would be 
biased and (2) information for the recalibration exercise would be 
lost. Because the outlier-substituting process changed the initially 
calculated APTM, it was iterated until the final one was reached. 
The limit used for outlier detection corresponded to 3 standard 
deviations. For FT4, 11 outliers from a total of 923 data were iden-
tified and adapted; for TSH, there were 29 out of 1,218. Outliers 
were excluded from calculation of the within-run coefficient of 
variation and between-run differences. 
 Status of Standardization/Harmonization before and after 
Recalibration 
 The status of standardization and the effect of recalibration by 
the IVD manufacturers based on their master calibrators were in-
vestigated from the assay biases (%; mean of duplicates) for each 
of the samples compared to the respective targets. Also the mean 
bias (%) of each assay relative to the mean target was assessed, i.e. 
by averaging the individual %-difference of the duplicate means 
from their respective target values. This was done for a low (FT4: 
<9 pmol/l; TSH: 0.03–0.5 mIU/l), mid- (FT4: 9–27 pmol/l; TSH: 
0.5–5 mIU/l), and high (FT4: >27 pmol/l; TSH: >5 mIU/l) concen-
tration range. Furthermore, the interassay variation for the indi-
vidual samples (‘interassay CV’) before and after recalibration was 
evaluated. It was calculated from the ratio between the standard 
deviation on each assay’s results per sample and the mean sample 
concentration (FT4) or APTM (TSH). For statistical analysis and 
plotting, Microsoft Excel ® 2010 was used.
 Results 
 Concentration Ranges Covered by the Clinical 
Samples 
 The clinical samples adequately addressed concentra-
tions typical for hypo-, eu-, and hypothyroidism, i.e. 
ranging from 3 to 77 pmol/l for FT4 (cRMP targets), and 
from 0.04 to 80 mIU/l for TSH (APTM)  [21, 22] .
 Status of Standardization before and after 
 Figure 1 A and  table  3 show that, compared to the 
cRMP targets, all FT4 assays were strongly negatively 
 biased (beyond the arbitrary limit of –10%) for con-
centrations >27 pmol/l (median bias: –37%, range: –21
to –48), and between 9 and 27 pmol/l (median bias: –24%, 
range: –14 to –42). In contrast, they were negatively as 
well as positively biased in the range <9 pmol/l (median 
bias: –9%, range: –28 to 62). IVD manufacturers were 
able to eliminate the observed bias of their assays by reca-
libration to the cRMP target values ( fig. 1 c).
 Figure 1 b and  table 3 demonstrate that for TSH, the 
assays’ mean bias to the APTM was slightly more negative 
in the low concentration range (0.03–0.05 mIU/l; median 
bias: –6%; range: –33 to 12) than in the mid-range (0.05–
5 mIU/l; median bias: –2%; range: –23 to 11) and >5 
mIU/l (median bias: –0.3%; range: –21 to 12). The num-
ber of TSH assays outside the ±10% limit around the 
APTM was between 2 and 5 out of 14, dependent on the 
 Table 3.  Assay bias (mean %) vs. the ED ID-LC/tandem MS cRMP 
or APTM (before and after recalibration)
FT4
assay
Before recalibration After recalibration
<9
pmol/l
9 – 27
pmol/l
>27
pmol/l
<9
pmol/l
9 – 27
pmol/l
>27
pmol/l
M 38 –14 –33 17 –0.9 –3.5
E 62 –18 –43 66 –7.8 –6.1
G 4.6 –20 –34 –8.5 1.7 –1.6
B –28 –20 –21 –12 –1.5 –2.2
H 23 –22 –42 23 0.2 1.0
D 26 –23 –41 31 –0.1 1.4
I –18 –24 –30 13 4.6 –3.6
C –10 –25 –37 16.1 4.8 –6.9
A –27 –26 –27 –9.2 –7.8 –8.6
L 5.7 –28 –45 –15 0.5 –1.2
J –9.3 –29 –37 –5.6 3.2 –0.2
F –27 –37 –48 –8.9 2.7 0.2
K –15 –42 –45 19 1.9 2.1
TSH
assay
Before recalibration  After recalibration
0.03 – 0.5
mIU/l
0.5 – 5
mIU/l
>5
mIU/l
0. 03 – 0.5
mIU/l
0.5 – 5
mIU/l
>5
mIU/l
I –33 –23 –21 –10 0.8 –1.1
A –7.7 –8.4 –17 –5.9 5.0 5.2
J –10 –6.2 –2.3 4.3 1.4 –0.4
M –8.7 –5.4 –0.3 –8.3 –6.7 –3.3
L –3.6 –3.8 –6.8 –2.0 –0.7 –0.5
F –19 –1.9 –0.3 –19 –2.7 1.8
H –7.4 –1.9 7.4 –2.8 0.0 –0.3
N –3.7 –1.4 3.5 –0.8 –3.0 –0.3
D 4.4 0.7 –1.2 5.6 1.4 –0.2
G –19 1.2 4.6 –21 –0.3 3.8
E 7.6 7.7 7.6 –2.0 –0.9 –1.9
K 12 8.3 12 –3.6 –1.5 –1.4
C –2.1 9.4 8.4 –10 1.5 –1.2
B 4.4 11 –17 –15 1.4 6.0
 Biases before recalibration sorted in ascending order (FT4 in 
the concentration range 9 – 27 pmol/l and TSH in the range 0.5 – 5 
mIU/l).
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 Fig. 1.  a–d Plots showing the %-difference before (FT4:  a , TSH:  b ) and after recalibration (FT4:  c , TSH:  d ). The 
most discrepant assays before recalibration are highlighted by special symbols (FT4: K, circles; M, triangles; TSH: 
I, circles; K, triangles); all other assays are indicated with the same symbol X.  e ,  f Interassay CV (FT4:  e , TSH:  f ) 
before (squares) and after (triangles) recalibration by IVD manufacturers. 
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concentration range. After recalibration to the APTM, 
the distribution of the differences around zero became 
more symmetric ( fig. 1 d). 
 The effect of recalibration to the respective targets can 
also be inferred from the decrease in interassay CVs, 
which ranged from 9.7% (mid-concentration range, be-
fore recalibration) to 3.4% (after) for FT4 ( fig.  1 e); for 
TSH it ranged from 9.1% (also mid-range) to 5.9% ( fig. 1 f).
 Discussion 
 C-STFT conducted this phase III method comparison 
study for FT4 and TSH to reconfirm the feasibility and 
investigate the impact of standardization/harmonization 
on a clinically relevant concentration range. The empha-
sis was on remediating limitations of previous studies by 
using samples representing a broad thyroid spectrum and 
sourced from clinical settings. However, samples from 
patient categories, on which immunoassays are known to 
be design-dependent flawed, e.g. pregnant females or pa-
tients with nonthyroidal illness (NTI), were purposely ex-
cluded as this would jeopardize the use of a uniform re-
calibration basis unless the design was adapted/optimized 
by the manufacturer  [23, 24] . As previously, the results 
are reported without identification of the assay/manufac-
turer  [12–14, 18] , which was a carefully thought-out deci-
sion to protect the integrity and long-term objectives of 
the project (see the explanation in the online suppl. mate-
rial). Note, however, that it is the intention to disclose the 
identity upon publishing the final standardization/har-
monization study. 
 Status of Standardization 
 The status of standardization/harmonization was 
judged by applying an arbitrary limit. Immunoassay per-
formance within 10% from a hierarchically higher refer-
ence (the ED ID-LC/tandem MS cRMP for FT4, the 
APTM for TSH) was considered state of the art  [13, 18] . 
For FT4, it was exceeded by far by all immunoassays. In 
the mid- to high concentration range, they all were 
strongly negatively biased. In contrast, for concentrations 
<9 pmol/l, six assays tended to positive deviations. In ad-
dition, the data showed a considerable between-assay dis-
crepancy. This was inferred from a difference between the 
assays that gave the lowest and highest FT4 results in the 
order of approximately 30% (assays K and M in the range 
of 9–27 pmol/l, F and B in the range >27 pmol/l) to even 
approximately 90% (assay B and E in the range <9 pmol/l). 
This reconfirmed that, currently, FT4 measurement re-
sults outside the range of one assay are well within that of 
another, which can confuse clinicians when they do not 
consider assay-specific reference intervals.
 For TSH, concentration-dependent differences to the 
APTM and interassay were also observed; however, they 
remained for the greater part within 10%. In the mid-
concentration range, the assays even compared fairly 
well since only two deviated by more than 10%. In the 
pathophysiological ranges (<0.5 and >5 mIU/l, respec-
tively), the numbers were somewhat higher (5 and 4, re-
spectively). Nevertheless, the discrepancy between the 
most extreme assays was considerable since one (assay I) 
negatively deviated by –21 to –33%, while another (assay 
K) was positively biased by 8–12%. Other assays switched 
in a concentration-dependent manner from a negative 
to a positive bias. These observations emphasize that 
harmonization is necessary, especially in light of current 
clinical practice discussions regarding decision limits in 
absolute values, e.g. 4.5 mIU/l in adults and or 2.5 mIU/l 
in pregnancy  [25–28] . Consequently, until harmoniza-
tion is reached, journals should emphasize the need to 
identify the assay used to generate data in clinical stud-
ies. 
 The excellent correlation of each of the TSH assays to 
the APTM (correlation coefficients at least 0.995) sup-
ports the argument that current immunoassays are ‘gly-
cosylation blind’, in spite of the evidence that both core 
and terminal glycosylation alter epitope expression in 
TSH  [19] . A second argument against pathophysiologi-
cal-specific glycosylation as a potential cause of measure-
ment discordance is that for most assays there was neither 
an obvious indication of sample-related effects (see on-
line suppl. fig. S2), nor of a different performance on par-
ticular sample groups (apart from a calibration issue in 
the low concentration range for three assays).
 In general, the study strengthened our past findings 
that, standardization/harmonization would be of great 
benefit for both FT4 and TSH, especially in the low con-
centration range. 
 Success of Recalibration 
 For FT4, recalibration markedly improved the agree-
ment of the assays with the cRMP ( fig. 1 c), although it 
appears that for most assays recalibration in the low con-
centration range can be improved (online fig. S1).
 For TSH, on the other hand, recalibration mainly cen-
tered the distribution of the assay differences around zero 
( fig. 1 d, online suppl. fig. S2). In general, the success of 
recalibration for the entire concentration range was good; 
however, for certain assays (F, G, and B in online suppl. 
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fig. S2), it was poor, <0.30 mIU/l, with differences up to 
approximately –80%. For assay C, a peculiar shape in the 
difference plot was observed after recalibration, most 
probably due to the use of distinct recalibration functions 
for low and high concentrations. In fact, this phenome-
non was already present in the initial data, and recalibra-
tion did not correct it. 
 Overall, for most recalibrated FT4 and TSH assays, the 
remaining total error is nearly entirely due to random er-
ror components. An additional measure of the benefits of 
recalibration is the interassay CV ( fig. 1 e, f). For both an-
alytes, it decreases significantly below 10% for the major-
ity of the samples (apart from those with low concentra-
tions), indicating the improved closeness of results. 
 Although standardization/harmonization is techni-
cally feasible, at least for the clinical samples used in this 
study, there is still a long road to go before implementa-
tion will become effective. Besides some straightforward 
technical issues, such as the establishment of infrastruc-
ture to sustain standardization/harmonization, it will be 
essential for the C-STFT to openly collaborate with a 
broad spectrum of representatives with a stake in ensur-
ing reliable laboratory testing for optimal/efficient man-
agement of patients with thyroid disease. These repre-
sentatives should include laboratory directors, regulato-
ry agencies, professional societies, pharmaceutical 
companies, and of course physicians and their patients. 
They will, for example, have to agree on the best point in 
time for global implementation (all assays/all manufac-
turers), and discuss whether, after implementation, a 
broader spectrum of samples should be used to study the 
influence of certain clinical factors on assay performance, 
e.g. glycoheterogeneity and NTI. This might help to de-
cide which patient categories should, if any, be deemed 
for measurement with current immunoassays (e.g. as 
recommended by the National Academy of Clinical Bio-
chemistry for NTI and others  [29, 30] ), and/or call for 
new assay generations with dedicated designs. Medical 
journals and professional societies should serve as addi-
tional vehicles. 
 Indeed, to avoid interpretation errors, the impact of 
recalibration on the numerical values obtained by indi-
vidual immunoassays (thus, on their reference interval 
or decision limits) will require transition with caution. 
This study showed that particularly for FT4 assays the 
impact will be huge. The current calibration set point will 
increase between approximately 15 and 50% (in the mid- 
to high concentration range). For example, for a specific 
sample before recalibration, assays K and M report ap-
proximately 10.5 pmol/l and 15.8 pmol/l, respectively; 
afterwards both would report approximately 19 pmol/l. 
In contrast, for TSH the impact will not be as dramatic 
since only 3–4 assays will be significantly affected (1 over 
the whole concentration range, 2 in the low range, and 1 
in the high range). From this perspective, C-STFT con-
siders the establishment of the physician/laboratory-in-
terface of particular importance within the relationship 
of all stakeholders. The endocrine societies and the IFCC 
should establish a joint committee to address these is-
sues.
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